ArticleNutrients2025
Lipoprotein(a) Response to Dietary Saturated Fat Reduction: Relationship to Apolipoprotein(a) Size Polymorphism in African Americans.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lipoprotein(a) lipidome and diet: responses to reducing saturated fat intake in African Americans in a randomized trial.Journal of lipid research · 2026Trial
- Characterizing Lipoprotein(a) in Children With New-Onset Diabetes and Implications for Cardiovascular Risk Assessment.Journal of the Endocrine Society · 2025Article
- Lipoprotein(a) and Effects of Diet: Time for Reassessment.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
objectivesAn elevated lipoprotein(a) [Lp(a)] level, which is a prevalent cardiovascular risk factor, is genetically determined by a size polymorphism of its apolipoprotein(a) [apo(a)] component. Despite its genetic control, Lp(a) level increases in response to dietary saturated fat (SFA) reduction. We tested the roles of apo(a) size and characteristics in modulating Lp(a) response to SFA reduction.
methodsWe assessed apo(a) characteristics in 165 African Americans experiencing a 24% Lp(a) increase resulting from SFA reduction [16% at an average American Diet diet (AAD) to 6% at a DASH-type diet]. Apo(a) effects were tested based on the following factors: (1) the presence of a small atherogenic size (≤22 kringles), (2) phenotype (single or two isoforms), (3) isoform dominance, and (4) tertiles of combined kringle sizes.
resultsThere were no significant differences in Lp(a) increases between carriers vs. non-carriers of a small apo(a), between those with a single vs. two expressed isoforms, or in those with differing isoform dominance patterns (
conclusionsReducing dietary SFA intake results in a 24% increase in Lp(a) level in African Americans across apo(a) sizes. Individuals with smaller apo(a) sizes reached an elevated Lp(a) level post-intervention compared to those with larger sizes, in some cases resulting in cardiovascular risk reclassification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.